Mesenkia Therapeutics is a pre-clinical company built on state-of-the art research from the prominent Universities of Tokyo and Uppsala with the focus on prolonging progression free survival for patients with aggressive primary and recurrent glioblastoma.
Mesenkia has an exciting program with a unique first-in-class biologic with the potential to reduce tumour volume and prolong survival in in patients with aggressive malignant brain tumours.
Company Details
- Employees
- 3
- Founded
- 2023
- Address
- Uppsala, Se
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Stockholm.
- HQ
- Uppsala
Mesenkia Therapeutics Ab Questions
Mesenkia Therapeutics Ab's website is https://mesenkiatherapeutics.com/
Mesenkia Therapeutics Ab's LinkedIn profile is https://se.linkedin.com/company/mesenkia
Mesenkia Therapeutics Ab has
3 employees.
View email and phone details for 3
employees at Mesenkia Therapeutics Ab.
Mesenkia Therapeutics Ab's industry is
Biotechnology Research
Mesenkia Therapeutics Ab's top competitors are
Mycural Therapeutics,
Augmentedrealm,
Ribocure Pharmaceuticals Ab,
Sally R,
Almi Invest,
Readily Diagnostics,
Upup,
Phenaros,
Rarity Bioscience,
Cellda Ab.
Mesenkia Therapeutics Ab's categories are Biotechnology Research
Mesenkia Therapeutics Ab's founding year is 2023
